Next earnings date: 5 Aug 2025
NexImmune, Inc. – NASDAQ:NEXI
NexImmune stock price today
$0
-0.20
-99.95%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
NexImmune stock price monthly change
-94.68%
month
NexImmune stock price quarterly change
-94.68%
quarter
NexImmune stock price yearly change
-90.13%
year
NexImmune key metrics
Market Cap | 348.66K |
Enterprise value | N/A |
P/E | -0.16 |
EV/Sales | N/A |
EV/EBITDA | 0.31 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -24.14 |
Revenue | N/A |
EBITDA | -24.60M |
Income | -25.85M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNexImmune stock price history
NexImmune stock forecast
NexImmune financial statements
| Jun 2023 | 0 | -7.56M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.85M | |
| Dec 2023 | 2.12M | -5.35M | -252.7% |
| Mar 2024 | 0 | -3.07M |
| 2027 | 0 | -1.00M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-04-16 | -5.85 | -4.99 |
|---|
| Jun 2023 | 23473948 | 6.47M | 27.57% |
|---|---|---|---|
| Sep 2023 | 14561694 | 6.30M | 43.32% |
| Dec 2023 | 8593949 | 5.08M | 59.16% |
| Mar 2024 | 8990613 | 6.02M | 67% |
| Jun 2023 | -6.02M | -5.01K | 0 |
|---|---|---|---|
| Sep 2023 | -7.28M | 3.24K | 0 |
| Dec 2023 | -5.83M | -44.44M | 0 |
| Mar 2024 | -2.41M | 522.55K | 3.14M |
NexImmune alternative data
| Aug 2023 | 50 |
|---|---|
| Sep 2023 | 50 |
| Oct 2023 | 50 |
| Nov 2023 | 50 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
NexImmune other data
10.92%
-13.49%
of NEXI is owned by hedge funds
18
-10
2.62M
-3.33M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 7825 |
| Jun 2024 | 1 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | JONES KRISTI director, officer.. | Series A Preferred Stock, par value $0.0001 per share | 1 | $0.01 | $0 | ||
Sale | ROEMER ALAN S. director | Common Stock | 3,992 | $1.94 | $7,756 | ||
Sale | ROEMER ALAN S. director | Common Stock | 3,833 | $2.16 | $8,287 | ||
Purchase | BARER SOL J director | Common Stock | 400,000 | $0.41 | $164,000 | ||
Purchase | BARER SOL J director | Common Stock | 75,000 | $0.48 | $35,925 | ||
Purchase | BARER SOL J director | Common Stock | 125,000 | $0.48 | $60,250 | ||
Purchase | VERSTANDIG GRANT director | Common Stock | 26,876 | $2.28 | $61,385 | ||
Purchase | VERSTANDIG GRANT director | Common Stock | 25,000 | $2.14 | $53,550 | ||
Purchase | VERSTANDIG GRANT director | Common Stock | 15,000 | $2.23 | $33,375 | ||
Purchase | BARER SOL J director | Common Stock | 20,720 | $2.23 | $46,102 |
| Patent |
|---|
Grant Filling date: 9 Dec 2019 Issue date: 18 May 2021 |
Application Filling date: 18 Mar 2020 Issue date: 24 Sep 2020 |
Application Filling date: 17 Mar 2017 Issue date: 17 Sep 2020 |
Grant Filling date: 24 Dec 2015 Issue date: 28 Apr 2020 |
| Insider | Compensation |
|---|---|
| Mr. Scott P. Carmer (1965) Chief Executive Officer & Director | $518,360 |
| Ms. Kristi Jones (1963) Chief Operating Officer | $397,480 |
Mr. John Trainer M.B.A. (1974) Chief Financial Officer | $342,440 |
-
What's the price of NexImmune stock today?
One share of NexImmune stock can currently be purchased for approximately $0.
-
When is NexImmune's next earnings date?
NexImmune, Inc. is estimated to report earnings on Tuesday, 5 Aug 2025.
-
Does NexImmune pay dividends?
No, NexImmune does not pay dividends.
-
How much money does NexImmune make?
NexImmune has a market capitalization of 348.66K. NexImmune made a loss 32.34M US dollars in net income (profit) last year or -$4.99 on an earnings per share basis.
-
What is NexImmune's stock symbol?
NexImmune, Inc. is traded on the NASDAQ under the ticker symbol "NEXI".
-
What is NexImmune's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NexImmune?
Shares of NexImmune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NexImmune's key executives?
NexImmune's management team includes the following people:
- Mr. Scott P. Carmer Chief Executive Officer & Director(age: 60, pay: $518,360)
- Ms. Kristi Jones Chief Operating Officer(age: 62, pay: $397,480)
- Mr. John Trainer M.B.A. Chief Financial Officer(age: 51, pay: $342,440)
-
How many employees does NexImmune have?
As Jul 2024, NexImmune employs 6 workers, which is 73% less then previous quarter.
-
When NexImmune went public?
NexImmune, Inc. is publicly traded company for more then 4 years since IPO on 12 Feb 2021.
-
What is NexImmune's official website?
The official website for NexImmune is neximmune.com.
-
Where are NexImmune's headquarters?
NexImmune is headquartered at 9119 Gaither Road, Gaithersburg, MD.
-
How can i contact NexImmune?
NexImmune's mailing address is 9119 Gaither Road, Gaithersburg, MD and company can be reached via phone at +30 18259810.
NexImmune company profile:
NexImmune, Inc.
neximmune.comExchange:
NASDAQ
Full time employees:
6
Industry:
Biotechnology
Sector:
Healthcare
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
9119 Gaither Road
Gaithersburg, MD 20877
Gaithersburg, MD 20877
CIK: 0001538210
ISIN: US65344D2080
CUSIP: 65344D109
